Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 34% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-06-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: priorsubjectto dayradiationchemotherapy
  Phrases that lowered it: participantparticipantssafetydailycombination
• Sponsor's past termination rate: 50% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Collaborators: 2 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 13083 (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports before start: 49009 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) NCT04314089 · started 2020 · scored riskier than 79% of active trials completed
• Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC NCT03573947 · started 2018 · scored riskier than 97% of active trials completed
• Genetic Predictors of Benefit to Pembrolizumab NCT02710396 · started 2016 · scored riskier than 93% of active trials terminated
• Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer NCT02963090 · started 2017 · scored riskier than 84% of active trials terminated
• Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 NCT03003468 · started 2017 · scored riskier than 98% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.